Consultation closing 13 Nov: Primary Maternity Services Notice Review 2021
The Ministry of Health is consulting on proposed changes to the Maternity Services Notice. The draft notice plus a discussion document and feedback form are on the Ministry’s website. The consultation period is until 13 November 2020. Te Kāhui Oranga ō Nuku has met with the Ministry of Health in a consultation meeting and is finalising a submission.
Consultation: Health and disability services standard
Te Kāhui Oranga ō Nuku will prepare a submission on the public consultation on the Health and disability services standard. You can view or download the draft standard on the Standards New Zealand website . The closing date for submissions is 13 January 2021.
NZS 8134: 2008 – Health and disability services standard is designed as the minimum requirements necessary to present fair and equitable health and disability services that aim to improve the experience and outcomes of people and whānau and reduce care variation.
Following consultation with the sector, NZS 8134:2008 - Health and Disability Services Standards, NZS 8181:2007 - Fertility Services Standard, and NZS 8158:2012 - Home and Community Support Sector Standard, have been amalgamated to form NZS 8134:2021 – Health and Disability Services Standard, significantly reducing duplication across the three standards.
Abstract submission deadline 23 November for RANZCOG ASM 2021
The deadline for abstract submissions for the 2021 RANZCOG ASM, to be held virtually from 15-18 February is 5pm 23 November 2020. For further information see https://ranzcogasm.com.au/submit-abstract/. The RANZCOG ASM 2021 theme is: A vision for the future.
HDC appoints new Commissioner
HDC has a new Health and Disability Commissioner.
Morag Powell replaces outgoing HDC Anthony Hill. Te Kāhui Oranga ō Nuku will be meeting with the new HDC along with Deputy Commissioner Rose Wall and HDC staff at the end of their November meeting.
The Health & Disability Commissioner publishes its reports on the outcome of complaints investigated - see https://www.hdc.org.nz/decisions/
Learn about recent decisions:
He Hono Wahine Hui 2020
RANZCOG NZ Fellows and trainees, PGYs, medical students and others with an interest in hauora wāhine gathered for the RANZCOG He Hono Wāhine Hui-a-tau 2020 at Ōwhata Marae in Rotorua last month.
The huge amount of mahi by He Hono Wāhine members and others in putting on another successful Hui-a-tau is acknowledged. Attendees provided feedback on their experience:
“I had such a great time…from a practical perspective the session on the marae ātea where O&G Doctors shared their journeys and tips was probably the most helpful in terms of getting me thinking about things that I could do or should be thinking about….I also really enjoyed the hapū wānanga sessions with Māori midwives…”
“I absolutely loved attending this weekend hui. Made a lot of good connections with people who could provide valuable insight into what O&G is like as a career option for me…”
“Just wanted to once again say a massive thank you…I felt very privileged to be there and left feeling both motivated and refreshed.”
“…as a student seeing Māori health professionals creating positive change within the field is so inspiring”
Women of Influence Awards 2020 finalists
RANZCOG New Zealand acknowledges 2020 Women of Influence Awards finalists Professor Beverley Lawton (He Hono Wāhine member) and Professor Suzanne Pitama (MIHI course facilitator) in the Innovation, Science & Health category.
The Women of Influence 2020 winners will be announced on November 17. For more information about the Awards, visit www.womenofinfluence.co.nz
Mercia Barnes Trust 2021 funding round
The Mercia Barnes Trust invites applications for 2021 research fellowships in the area of women's and reproductive health up to a value of $35,000 each. The Mercia Barnes Trust specifically supports New Zealand research with a focus on supporting young researchers.
Applications close 5pm Friday 5 March 2021. Application forms and the form for referees will be available on the NZ page of the RANZCOG website shortly. For further information please see the RANZCOG website
or contact the RANZCOG NZ office at email@example.com
Updates to the Jadelle data sheet on the use in breastfeeding women
Medsafe advise that the New Zealand Data Sheet for Jadelle use in breastfeeding women has been updated. See www.medsafe.govt.nz/profs/Datasheet/j/Jadelleimplant.pdf.
More DHBs using NOC/NEWS tool to identify at-risk newborns
ACC advise five DHBs are implementing the Newborn Observation Chart and Newborn Early Warning Score (NOC/NEWS) tool for identifying newborn babies at risk of neonatal encephalopathy (NE) with another 14 in the planning phase. The aim is to have all 20 DHBs using this system in 2021.
The early warning system enables primary and secondary care maternity care providers to work together with women and their babies as one team. The NOC/NEWS tool is a core part of ACC’s wider NE prevention programme, helping to identify babies that might benefit from cooling early, potentially reducing the severity of long-term impacts on the baby.
Lesley Long, ACC NOC/NEWS Project Manager, can be contacted with any queries at Lesley.Long@acc.co.nz
Research Review publications are intended for NZ health professionals. To subscribe for free to receive a research review on a regular basis go to www.researchreview.co.nz
Ovarian Cancer Research Review
In the 11-2020 issue of Ovarian Cancer Research Review
there are articles on: Association between breastfeeding and ovarian cancer risk; Validation of models to diagnose ovarian cancer; Cytoreductive surgery with or without HIPEC for stage III epithelial ovarian cancer; Detection of TP53 clonal variants in Papanicolaou test samples collected up to 6 years prior to high-grade serous epithelial ovarian cancer diagnosis; Apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynaecologic malignant neoplasm; Quality-of-life results for weekly vs 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer; Guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers; Bevacizumab and platinum-based combinations for recurrent ovarian cancer; COVID-19 outcomes of patients with gynaecologic cancer in NY; GNRH agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours; Impact of dose reductions and delays on PFS in ovarian cancer treated with three-weekly or dose-dense carboplatin and paclitaxel regimens.
In the 12-2020 issue of Ovarian Cancer Research Review
there are articles on: ASCO guideline for PARP inhibitors in the management of OC; Efficacy of maintenance olaparib for newly diagnosed advanced OC with a BRCA mutation; Binimetinib vs physician’s choice chemotherapy in recurrent or persistent LGSC; Nomogram to determine long term survival outcomes of stage I mucinous OC; Safety of surveillance in stage IA-C G1-3 Its; Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for OC; Efficacy and toxicity of extended duration PLD in women with recurrent EOC; Nivolumab vs nivolumab and ipilimumab for recurrent or persistent OC; Olaparib and durvalumab for recurrent OC.
ESMO 2020 Conference Review - focus on Ovarian Cancer
In the Australian Research Review there is a review of the European Society for Medical Oncology (ESMO) Congress
which was held online from 19-21 September 2020. Articles include: IMagyn050 fails to confirm a benefit to the addition of atezolizumab to a bevacizumabbased regimen in EOC; Mature ICON8 results confirm no advantage to weekly dosing versus three-weekly chemotherapy for EOC; Olaparib maintenance confers a substantial clinical benefit in newly diagnosed, advanced, BRAC-mutated OC; MEDIOLA shows a benefit to olaparib/ durvalumab/bevacizumab in relapsed non BRAC-mutated OC; Subsequent chemotherapy for patients with BRCA1/2-mutated OC progressing on olaparib; RETOLA confirms the real-world efficacy of olaparib maintenance for BRCA-mutated relapsed EOC; Efficacy of platinum-based chemotherapy in platinum-resistant OC; Gemcitabine, cisplatin and bevacizumab for first recurrent and refractory ovarian clear-cell carcinoma.
New and updated Cochrane summaries for COVID-19 and O&G
Please see the latest summaries for COVID-19 from the Cochrane Library at www.cochranelibrary.com
on: Does quarantine, alone or in combination with other public health measures, control coronavirus (COVID-19)?; How effective is screening for COVID-19?; Can travel-related control measures contain the spread of the COVID-19 pandemic?; Does the use of antimicrobial mouthwash or nasal spray by people who are not actively suspected of having COVID-19 - or by their healthcare workers - protect their healthcare workers when they undertake 'aerosol-generating procedures' on them?; What are the benefits and risks of healthcare workers using antimicrobial mouthwashes or nasal sprays to protect themselves when they treat people with COVID-19?; What are the benefits and risks of people with COVID-19 using antimicrobial mouthwashes or nasal sprays to improve their health and protect healthcare workers who treat them?; How accurate is chest imaging for diagnosing COVID-19?; Is plasma from people who have recovered from COVID-19 an effective treatment for people with COVID-19?.
Please see the latest summaries for obstetrics and gynaecology from the Cochrane Library at www.cochranelibrary.com
on: Preimplantation genetic testing for abnormal chromosome numbers for couples undergoing in vitro fertilisation; Intrauterine progesterone-releasing system for treatment of endometrial hyperplasia; Cervical stitch (cerclage) in combination with other treatments for preventing premature or early birth of single babies.